Clinical Cancer Research Holland
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hui, A.-M.
Right arrow Articles by Makuuchi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hui, A.-M.
Right arrow Articles by Makuuchi, M.
Clinical Cancer Research Vol. 6, 4272-4277, November 2000
© 2000 American Association for Cancer Research

Regular Articles

Cyclin D1 Overexpression Is a Critical Event in Gallbladder Carcinogenesis and Independently Predicts Decreased Survival for Patients with Gallbladder Carcinoma1

Ai-Min Hui2, Xin Li, Ya-Zhou Shi, Tadatoshi Takayama, Guido Torzilli and Masatoshi Makuuchi

Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo 113-0033, Japan

ABSTRACT

This study was designed to test the hypothesis that cyclin D1 overexpression is involved in the multistep process of gallbladder carcinogenesis and can be used to predict poor prognosis for patients with gallbladder carcinoma (GBC). Cyclin D1 expression was examined immunohistochemically in a series of specimens, including 8 normal epithelia, 8 benign adenomyoma lesions, 6 precancerous adenomas, and 37 carcinomas of the gallbladder. Four of the 6 (67%) adenomas and 15 of the 37 (41%) adenocarcinomas demonstrated cyclin D1 overexpression (>5% nuclear staining), whereas all normal epithelia and adenomyoma lesions were negative for cyclin D1. Kaplan-Meier curves showed that cyclin D1 overexpression was significantly related to decreased overall survival (P < 0.05) in patients with GBCs. The Cox proportional hazards model identified cyclin D1 overexpression as an independent prognostic marker for death (P = 0.024; risk ratio, 4.2; 95% confidence interval, 1.2–14.7). To test whether cyclin D1 overexpression is a critical event in gallbladder neoplasms, cyclin-dependent kinase inhibitor p27Kip1 was introduced to ascertain how cyclin D1 affects clinical outcomes. Subsequently, neoplasms were divided into three groups on the basis of the combination of cyclin D1 expression and p27Kip1 status, which had been determined previously. Group 1 showed no abnormality in either cyclin D1 or p27Kip1 expression. Group 2 showed aberrant expression of one of the two proteins, whereas group 3 showed concurrent abnormalities in both proteins. Results indicated that overall survival was greatest in group 1, followed by a significant decrease in group 2 and a more precipitous decrease in group 3. In conclusion, cyclin D1 overexpression is an early event in gallbladder carcinogenesis and independently predicts decreased survival for patients with GBC.

INTRODUCTION

Multiple genetic or epigenetic changes contribute to the multistep process of human carcinogenesis, and some of these changes help with the monitoring of this multistep process. It is important to understand the carcinogenic process and its corresponding molecular basis for each type of cancer. For gallbladder carcinogenesis, the dysplasia to carcinoma and adenoma to carcinoma conventional progressions have been generally ascertained (1 , 2) . However, the molecular mechanism underlying the development and progression of GBC3 is not fully understood. This is possibly because of the relative rarity of GBC, which accounts for only 3% of gastrointestinal cancers and 0.5% of all human malignancies, limiting the number of tumor samples available for study. GBC is one of the most biologically virulent cancers and is difficult to cure by conventional procedures. Elucidation of its molecular basis may be helpful in developing and identifying prognostic biomarkers.

Escaping from normal cell cycle controls is critical for the various processes of carcinogenesis (3, 4, 5, 6) . Cell cycle regulators more often altered in cancers are those controlling G1-S-phase progression. G1-S transition is controlled through interaction of several types of molecules, including CDKs, their positive regulators, cyclins (cyclins D1, D2, D3, and E), and their negative regulators, CDK inhibitors and retinoblastoma protein. CDK inhibitors fall into two classes on the basis of their sequence homology: (a) the INK family, which includes p16INK4, p15INK4B, p18INK6A, and p19INK6B; and (b) the Cip/Kip family, which includes p21WAF1/Cip1, p27Kip1, and p57Kip2. Among these proteins controlling the G1-S transition, cyclin D1 is one of the most strongly implicated in tumorigenesis. Cyclin D1 exerts its effects on cell cycle progression via two mechanisms: (a) cyclin D1-CDK complexes inactivate retinoblastoma protein by phosphorylation; and (b) these complexes bind and sequester Cip/Kip proteins stoichiometrically (7) . Evidence for the oncogenic potential of cyclin D1 is provided by studies with numerous models, in which elevated expression of cyclin D1 shortens the G1 phase of the cell cycle and enhances malignant transformation (8, 9, 10, 11, 12) .

Cyclin D1 overexpression, either with or without gene amplification, has been shown in a variety of human malignancies, including breast (13, 14, 15, 16, 17, 18) , colon (19) , lung (20) , esophageal (21, 22, 23) , liver (24, 25, 26) , pancreatic (27) , tongue (28) , oral verrucous (29) , pharyngeal (30) , and laryngeal (31) cancers and has been identified as a prognostic biomarker for breast (16) , lung (20) , esophageal (22 , 23) , pancreatic (27) , tongue (28) , pharyngeal (30) , and laryngeal (31) cancers. The role of cyclin D1 in GBC has not been extensively studied. Recently, we showed that cyclin D1 overexpression is significantly associated with poor clinical outcomes for patients with extrahepatic bile duct cancer (32) , another type of biliary tract malignancy. Moreover, cyclin D1 overexpression has been suggested to be an early event in human breast (18) , lung (33) , and colon (34 , 35) carcinogenesis and in mouse skin carcinogenesis (36) . On the basis of this background, we postulated that cyclin D1 overexpression may be involved in the multistep process of gallbladder carcinogenesis and may be useful as a prognostic marker for GBC. To test this hypothesis, we attempted to study cyclin D1 expression using immunohistochemistry in a series of surgically resected specimens, including normal epithelium, benign lesion adenomyoma, adenoma, and adenocarcinoma of gallbladder from patients treated surgically who had been in a postoperative follow-up phase.

MATERIALS AND METHODS

Patients.
Thirty-seven GBC lesions surgically resected from 36 patients (one patient had two cancers) between January 1990 and April 1999 in our department were studied. There were 17 males and 19 females, with a median age of 65 years (age range, 45–84 years). The clinicopathological variables were evaluated following the General Rules for Surgical and Pathological Studies on Cancer of Biliary Tract of the Japanese Society of Biliary Surgery (37) . Cancers were staged following the TNM system of the International Union against Cancer (38) . The clinicopathological features are described in Table 1Citation . Surgical procedures included 23 cholecystectomies (single cholecystectomy or cholecystectomy with resection of <2 cm depth of the liver bed) and 13 extended operations (resection of adjacent organs in addition to the gallbladder). Four patients who underwent palliative surgery were excluded from survival analysis.


View this table:
[in this window]
[in a new window]

  		Table 1 %Clinicopathological features and Cyclin D1 expression in gallbladder carcinomas

 
The status of p27Kip1 expression in this group of GBCs has been studied previously (39) . The 37 tumors were classified as 16 tumors with decreased p27Kip1 expression (<50% of tumor cells showing nuclear p27Kip1 immunoreactivity), and 21 tumors with normal p27Kip1expression (>=50% of tumor cells showing nuclear p27Kip1 immunoreactivity).

Six surgically resected specimens of gallbladder adenomas were studied. None of the adenomas had foci of carcinoma in situ. Eight specimens of adenomyoma, as well as eight specimens of normal gallbladder epithelia obtained from healthy persons who had undergone cholecystectomy when donating partial livers for transplantation, were also included in this study.

Immunohistochemistry.
Five-µm-thick sections were cut from formalin-fixed paraffin-embedded tissue blocks and mounted on gelatin-coated glass slides. The sections were dewaxed in xylene, rehydrated through graded concentrations of ethanol, and then treated with 0.5% hydrogen peroxide at room temperature for 30 min to block endogenous peroxidase activity. The sections were immersed in 10 mM citrate buffer (pH 6.0) and processed in an autoclave for 10 min at 120°C for antigen retrieval (32 , 40) . Anti-cyclin D1 antibody (Clone DCS-6; NeoMarkers, Union City, CA; dilution, 1:50) was applied, and incubations were performed overnight at 4°C. Immunohistochemistry was performed by the avidin-biotin complex technique using the Vectastain ABC Elite kit (Vector Laboratories, Burlingame, CA) with 3,3'-diaminobenzidine tetrahydrochloride development and hematoxylin counterstaining. Negative controls were sections stained without the primary antibody. Nuclear staining was considered to indicate specific cyclin D1 immunoreactivity.

For each case, one section having the greatest area of tumor and one section containing noncancerous gallbladder epithelium were selected for immunohistochemical staining from the tissue blocks on the basis of observation of H&E-stained sections. The scoring of cyclin D1 immunoreactivity was based on examination of 10 high-power (x400) microscopic fields or total tumor (when tumor was smaller than 10 fields) for each case. According to a widely accepted criterion (17 , 18 , 23 , 26 , 30, 31, 32) , tumors that expressed strong immunoreactivity in >5% of the cells were considered cyclin D1 positive (overexpression). All slides were interpreted independently by two investigators (A-M. H. and X. L.) without knowledge of the patients’ clinical courses.

Statistical Analysis.
The associations between cyclin D1 expression and clinicopathological variables were assessed using the {chi}2 test. Survival curves were plotted using the Kaplan-Meier method and compared using the log-rank test (41) . The significance of various parameters for survival was analyzed by the Cox proportional hazards model (42) . P < 0.05 was considered statistically significant.

RESULTS

Normal gallbladder epithelia from either healthy persons or GBC patients were consistently negative with regard to cyclin D1 nuclear immunoreactivity (Fig. 1Citation A), demonstrating <1% positive cells. All eight adenomyoma lesions were also cyclin D1 negative (Fig. 1Citation B). For seven of these specimens, the percentage of positive epithelial cells was <1%, and in the eighth specimen cyclin D1 immunoreactivity was observed in 3% of the epithelial cells. Four of the six (67%) adenomas showed cyclin D1 overexpression (>5% positive cells; Fig. 1Citation C) with the percentage of positive cells ranging from 8% to 90%.



View larger version (157K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Examples of cyclin D1 immunohistochemical staining. Normal gallbladder epithelia (A) and an adenomyoma (B), both of which were cyclin D1 negative. C, an adenoma demonstrating cyclin D1 overexpression. D, a cyclin D1-negative carcinoma. E, a carcinoma demonstrating cyclin D1 overexpression (x350).

 
Twenty-two of the 37 GBCs were cyclin D1 negative (59%; Fig. 1Citation D), and the remaining 15 were cyclin D1 positive (41%; Fig. 1Citation E). For the 15 cyclin D1-positive cancers, the percentage of cyclin D1-positive cells ranged from 6% to 90%. Cyclin D1 expression was not related to any clinicopathological parameters such as age, tumor histological type, lymphatic metastasis, TNM stage, p27Kip1 expression status, or surgical procedure (Table 1)Citation .

The duration of follow-up of the patients ranged from 3–101 months (median follow-up, 28 months). The Kaplan-Meier method and log-rank test were used to evaluate the effect of cyclin D1 expression on postoperative survival in 32 patients with GBCs, excluding four patients who underwent nonradical surgery. The 3-year and 5-year overall survival rates were 68% and 53% for all of the 32 patients. The corresponding figures were 80% and 71% for the cyclin D1-negative group and 50% and 30% for the cyclin D1-positive group, respectively. Cyclin D1 overexpression significantly predicted reduced overall survival (Fig. 2Citation ; P < 0.05). Multivariate analysis by the Cox proportional hazards model identified cyclin D1 overexpression (P = 0.024; risk ratio, 4.2; 95% confidence interval, 1.2–14.7), decreased p27Kip1 expression (P = 0.024; risk ratio, 4.2; 95% confidence interval, 1.3–13.7), and TNM stage III/IV (P = 0.001; risk ratio, 5.9; 95% confidence interval, 1.5–23.0) as independent predictors of death. The 3-year and 5-year overall survival rates were 84% and 71% for the patients who underwent cholecystectomy and 40% and 0% for those treated by extended operations. There was a significant difference between the survival curves (P = 0.007, log-rank test); however, the surgical procedure had no significance as an independent prognostic factor in the Cox proportional hazards model analysis. The effect of surgical procedure on survival probably resulted from the influence of disease stage; indeed, 9 of the 13 patients who underwent extended operations had stage III or stage IV tumors.



View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Kaplan-Meier curves for overall survival according to cyclin D1 expression in 32 patients who underwent radical surgery for GBC. Tick marks indicate surviving patients and the duration of follow-up. P < 0.05, log-rank test.

 
Drawing together the data of our present study and the previous one (39) , in which <50% p27Kip1 nuclear staining was defined as decreased p27Kip1 expression, GBCs were classified into three groups on the basis of cyclin D1 and p27Kip1 expression: (a) group 1, no abnormality in either cyclin D1 or p27Kip1 expression (<=5% cyclin D1 and >=50% p27Kip1); (b) group 2, altered expression of one of the two proteins (>5% cyclin D1 and >=50% p27Kip1 or <=5% cyclin D1 and <50% p27Kip1); and (c) group 3, concurrent abnormalities in both proteins (>5% cyclin D1 and <50% p27Kip1). Kaplan-Meier curves showed that overall survival was significantly shorter in group 2 (n = 14) than in group 1 (n = 12) and was even shorter in group 3 [n = 6; Fig. 3Citation ; group 1 versus group 2, P < 0.05; group 2 versus group 3, P < 0.05; group 1 versus group 3, P < 0.01 (log-rank test)]. The 3-year and 5-year overall survival rates were 100% and 88% for group 1, 64% and 38% for group 2, and 17% and 17% for group 3.



View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Kaplan-Meier curves for overall survival according to the combination of cyclin D1 and p27Kip1 expression in 32 patients who underwent radical surgery for GBC. Tick marks indicate surviving patients and the duration of follow-up. Group 1, no abnormality in either cyclin D1 or p27Kip1 expression (<=5% cyclin D1 and >=50% p27Kip1); group 2, aberrant expression of one of the two proteins (>5% cyclin D1 and >=50% p27Kip1 or <=5% cyclin D1 and <50% p27Kip1); group 3, coincident abnormalities in the expression of both proteins (>5% cyclin D1 and <50% p27Kip1). Group 1 versus group 2, P < 0.05; group 2 versus group 3, P < 0.05; group 1 versus group 3, P < 0.01 (log-rank test).

 
DISCUSSION

The involvement of cyclin D1 overexpression has been reported previously in a wide range of human cancers. To determine the potential oncogenic role of cyclin D1 in human gallbladder carcinogenesis, we designed the present study to evaluate the levels of cyclin D1 expression in a series of surgically resected specimens including normal epithelia, adenomyoma lesions, precancerous adenomas, and adenocarcinomas of the gallbladder. Cyclin D1 overexpression was frequently observed in adenocarcinomas and even in adenomas, but not in any specimen of normal epithelium or adenomyoma. This strongly suggests that increased cyclin D1 expression is an early event in gallbladder carcinogenesis, probably playing a critical role in the transformation of gallbladder epithelial cells. Recently, cyclin D1 overexpression has also been observed in precursor lesions for other types of cancers, including breast hyperplasia (18) , atypical adenomatous hyperplasia of the lung (33) , and adenomatous polyps of the colon (34 , 35) .

It is interesting to note that, in this study, the frequency of cyclin D1 overexpression was higher in adenomas (67%) than in cancers (41%). There are two possible interpretations for this novel phenomenon: (a) in the process of gallbladder carcinogenesis, cyclin D1 overexpression may only be needed for establishment of the transformed phenotype, and in some cases it may no longer be needed for maintenance of the transformed phenotype once the lesions have become malignant; and (b) the dysplasia to carcinoma sequence, as well as the adenoma to carcinoma progression, and other routes also contribute to the development of GBCs. Overexpression of cyclin D1 may be involved only in the adenoma to carcinoma route of gallbladder carcinogenesis and may not be involved in other pathways.

The most important finding in this study is that accumulation of cyclin D1 adversely affects clinical outcome and serves as an independent marker predicting decreased survival for patients with GBC. This is easy to understand, because cyclin D1 shortens the G1 phase and accelerates the cell cycle (8) . We have recently found that deregulation of p27Kip1, another key protein in G1-S transition control, significantly correlates with poor prognosis for GBC patients (39) . To ascertain how cyclin D1 affects clinical outcome, p27Kip1 was introduced into this study. The postoperative survival rate was greatest in patients with no abnormality in either cyclin D1 or p27Kip1 expression, followed by a significant decrease in those with aberrant expression of one of the two proteins, and was even lower in those with concurrent abnormalities in both proteins (Fig. 3)Citation . These data suggest that cyclin D1 overexpression, together with reduced p27Kip1 expression, affects the clinical course of GBC.

In conclusion, cyclin D1 overexpression is an early event in gallbladder carcinogenesis and independently predicts poor prognosis for patients with resectable GBC.

FOOTNOTES

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported in part by Grant 12671207 for scientific research from the Ministry of Education, Science, Sports and Culture of Japan, by a grant from the Japan-China Medical Association of Japan, and by a grant from the Fujida Memorial Fund for Medical Research (a fund within the Japan Society for the Promotion of Science) of Japan (all to A-M. H.). Back

2 To whom requests for reprints should be addressed, at Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. Phone: 81-3-3815-5411, ext. 33321; Fax: 81-3-5684-3989; E-mail: amhui-tky{at}umin.ac.jp Back

3 The abbreviations used are: GBC, gallbladder carcinoma; CDK, cyclin-dependent kinase; TNM, tumor-node-metastasis. Back

Received 5/11/00; revised 7/28/00; accepted 8/22/00.

REFERENCES

  1. Kozuka S., Tsubone M., Yasui A., Hachisuka K. Relation of adenoma to carcinoma in the gallbladder. Cancer (Phila.), 50: 2226-2234, 1982.[CrossRef][Medline]
  2. Dowling G. P., Kelly J. K. The histogenesis of adenocarcinoma of the gallbladder. Cancer (Phila.), 58: 1702-1708, 1986.[CrossRef][Medline]
  3. Peter M., Herskowitz I. Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell, 79: 181-184, 1994.[CrossRef][Medline]
  4. Hunter T., Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79: 573-582, 1994.[CrossRef][Medline]
  5. Weinberg R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.[CrossRef][Medline]
  6. Sheer C. J. Cancer cell cycle. Science (Washington DC), 274: 1672-1677, 1996.[Abstract/Free Full Text]
  7. Sherr C. J., Roberts J. M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev., 13: 1501-1512, 1999.[Free Full Text]
  8. Quelle D. E., Ashmun R. A., Shurtleff S. A., Kato J-Y., Bar-Sagi D., Roussel H. F., Sheer C. J. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev., 7: 1559-1571, 1993.[Abstract/Free Full Text]
  9. Jiang W., Kahn S. M., Zhou P., Zhang Y. J., Cacace A. M., Infante A. S., Doi S., Santella R. M., Weinstein I. B. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene, 8: 3447-3457, 1993.[Medline]
  10. Wang T. C., Cardiff R. D., Zukerberg L., Lees E., Arnold A., Schmidt E. V. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature (Lond.), 369: 669-671, 1994.[CrossRef][Medline]
  11. Hinds P. W., Dowdy S. F., Ng Eaton E., Arnold A., Weinberg R. A. Function of a human cyclin gene as an oncogene. Proc. Natl. Acad. Sci. USA, 91: 709-713, 1994.[Abstract/Free Full Text]
  12. Lovec H., Sewing A., Lucibello F. C., Muller R., Moroy T. Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation. Oncogene, 9: 323-326, 1994.[Medline]
  13. Bartkova J., Lukas J., Muller H., Lutzøft D., Strauss M., Bartek J. Cyclin D1 protein expression and function in human breast cancer. Int. J. Cancer, 57: 353-361, 1994.[Medline]
  14. Gillett C., Fantl V., Smith R., Fisher C., Bartek J., Dickson C., Barnes D., Peters G. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res., 54: 1812-1817, 1994.[Abstract/Free Full Text]
  15. Zhang S-Y., Caamano J., Cooper F., Guo X., Klein-Szanto J. P. K. Immunohistochemistry of cyclin D1 in human breast cancer. Am. J. Clin. Pathol., 102: 695-698, 1994.[Medline]
  16. McIntosh G. G., Anderson J. J., Milton I., Steward M., Parr A. H., Thomas M. D., Henry A. B., Angus B., Lennard T. W., Horne C. H. Determination of the prognostic value of cyclin D1 expression in breast cancer. Oncogene, 11: 885-891, 1995.[Medline]
  17. van Diest P. J., Michalides R. J. A. M., Jannink I., van der Valk P., Peterse H. L., de Jong J. S., Meijer C. J. L. M., Baak J. P. A. Cyclin D1 expression in invasive breast cancer: correlations and prognostic value. Am. J. Pathol., 150: 705-711, 1997.[Abstract]
  18. Alle K. M., Henshall S. M., Field A. S., Sutherland R. L. Cyclin D1 protein is overexpressed in hyperplasia and intraduct carcinoma of the breast. Clin. Cancer Res., 4: 847-854, 1998.[Abstract]
  19. Bartkova J., Lukas J., Strauss M., Bartek T. The PRAD-1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas. Int. J. Cancer, 58: 568-573, 1994.[Medline]
  20. Keum J. S., Kong G., Yang S. C., Shin D. H., Park S. S., Lee J. H., Lee J. D. Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer. Br. J. Cancer, 81: 127-132, 1999.[CrossRef][Medline]
  21. Jiang W., Kahn S. M., Tomita N., Zhang Y-J., Lu S-H., Weinstein I. B. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res., 52: 3980-3983, 1992.[Abstract/Free Full Text]
  22. Shinozaki H., Ozawa H., Ando N., Tsuruta M., Terada M., Ueda M., Kitajima M. Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus. Clin. Cancer Res., 2: 1155-1161, 1996.[Abstract]
  23. Ishikawa T., Furihata M., Ohtsuki Y., Murakami H., Inoue A., Ogoshi S. Cyclin D1 overexpression related to retinoblastoma protein expression as a prognostic marker in human oesophageal squamous cell carcinoma. Br. J. Cancer, 77: 92-97, 1998.[Medline]
  24. Zhang Y-J., Jiang W., Chen C. J., Lee C. S., Kahn S. M., Santella R. M., Weinstein B. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem. Biophys. Res. Commun., 196: 1010-1016, 1993.[CrossRef][Medline]
  25. Nishida N., Fukuda Y., Komeda T., Kita R., Sando T., Fukukawa M., Amenomori M., Shibagaki I., Nakao K., Ikenaga M., Ishizaki K. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res., 54: 3107-3110, 1994.[Abstract/Free Full Text]
  26. Ito Y., Matsuura N., Sakon M., Miyoshi E., Noda K., Takeda T., Umeshita K., Nagano H., Nakamori S., Dono K., Tsujimoto M., Nakahara M., Nakao K., Taniguchi N., Monden M. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology, 30: 90-99, 1999.[CrossRef][Medline]
  27. Gansauge S., Gansauge F., Ramadani M., Stobbe H., Rau B., Harada N., Beger H. G. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res., 57: 1634-1637, 1997.[Abstract/Free Full Text]
  28. Bova R. J., Quinn D. I., Nankervis J. S., Cole I. E., Sheridan B. F., Jensen M. J., Morgan G. J., Hughes C. J., Sutherland R. L. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin. Cancer Res., 5: 2810-2819, 1999.[Abstract/Free Full Text]
  29. Gimenez-Conti I. B., Collet A. M., Lanfranchi H., Itoiz M. E., Luna M., Xu H-J., Hu S-X., Benedict W. F., Conti C. J. p53, Rb, and cyclin D1 expression in human oral verrucous carcinomas. Cancer (Phila.), 78: 17-23, 1996.[CrossRef][Medline]
  30. Michalides R., van Veelen N., Hart A., Loftus B., Wientjens E., Balm A. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res., 55: 975-978, 1995.[Abstract/Free Full Text]
  31. Pignataro L., Pruneri G., Carboni N., Capaccio P., Cesana B. M., Neri A., Buffa R. Clinical relevance of cyclin D1 protein overexpression in laryngeal cell carcinoma. J. Clin. Oncol., 16: 3069-3077, 1998.[Abstract/Free Full Text]
  32. Hui A-M., Cui X., Makuuchi M., Li X., Shi Y-Z., Takayama T. Decreased p27Kip1 expression and cyclin D1 overexpression, alone and in combination, influence recurrence and survival of patients with resectable extrahepatic bile duct carcinoma. Hepatology, 30: 1167-1173, 1999.[CrossRef][Medline]
  33. Kurasono Y., Ito T., Kameda Y., Nakamura N., Kitamura H. Expression of cyclin D1, retinoblastoma gene protein, and p16 MTS1 protein in atypical adenomatous hyperplasia and adenocarcinoma of the lung. Virchows Arch., 432: 207-215, 1998.[CrossRef][Medline]
  34. Arber N., Hibshoosh H., Moss S. F., Sutter T., Zhang Y., Begg M., Wang S., Weinstein I. B., Holt P. R. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology, 110: 669-674, 1996.[CrossRef][Medline]
  35. Zhang T., Nanney L. B., Luongo C., Lamps L., Heppner K. J., DuBois R. N., Beauchamp R. D. Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Cancer Res., 57: 169-175, 1997.[Abstract/Free Full Text]
  36. Robles A. I., Conti C. J. Early overexpression of cyclin D1 protein in mouse skin carcinogenesis. Carcinogenesis (Lond.), 16: 781-786, 1995.[Abstract/Free Full Text]
  37. Japanese Society of Biliary Surgery. General Rules for Surgical and Pathological Studies on Cancer of Biliary Tract45-61, Kanehara Co., Ltd. Tokyo 1993.
  38. Sobin, L. H., and Wittekind, C. Gallbladder. In: NM Classification of Malignant Tumors, pp. 78–80. New York: Wiley-Liss, Inc., 1997.
  39. Hui A-M., Li X., Shi Y-Z., Torzilli G., Takayama T., Makuuchi M. p27Kip1 expression in normal epithelia, precancerous lesions and carcinomas of the gall-bladder: association with cancer progression and prognosis. Hepatology, 31: 1068-1072, 2000.[CrossRef][Medline]
  40. Hui A-M., Li X., Makuuchi M., Takayama T., Kubota K. Over-expression and lack of retinoblastoma protein are associated with tumor progression and metastasis in hepatocellular carcinoma. Int. J. Cancer, 84: 604-608, 1999.[CrossRef][Medline]
  41. Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.[CrossRef]
  42. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer, 35: 1-39, 1977.[Medline]



This article has been cited by other articles:


Home page
 J. Clin. Pathol.Home page
B Luzar, M Poljak, A Cor, U Klopcic, and V Ferlan-Marolt
Expression of human telomerase catalytic protein in gallbladder carcinogenesis
J. Clin. Pathol., August 1, 2005; 58(8): 820 - 825.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. R. Spitz, X. Wu, and G. Mills
Integrative Epidemiology: From Risk Assessment to Outcome Prediction
J. Clin. Oncol., January 10, 2005; 23(2): 267 - 275.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Varga, P. Obrist, S. Schneeberger, G. Muhlmann, C. Felgel-Farnholz, D. Fong, M. Zitt, T. Brunhuber, G. Schafer, G. Gastl, et al.
Overexpression of Epithelial Cell Adhesion Molecule Antigen in Gallbladder Carcinoma Is an Independent Marker for Poor Survival
Clin. Cancer Res., May 1, 2004; 10(9): 3131 - 3136.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hui, A.-M.
Right arrow Articles by Makuuchi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hui, A.-M.
Right arrow Articles by Makuuchi, M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online